Equities Analysts Offer Predictions for Heron Therapeutics, Inc.’s Q1 2024 Earnings (NASDAQ:HRTX)

Heron Therapeutics, Inc. (NASDAQ:HRTX) – Analysts at Capital One Financial issued their Q1 2024 earnings per share estimates for Heron Therapeutics in a research report issued to clients and investors on Tuesday, April 23rd. Capital One Financial analyst T. Chiang expects that the biotechnology company will post earnings per share of ($0.09) for the quarter. Capital One Financial currently has a “Overweight” rating and a $6.00 price objective on the stock. The consensus estimate for Heron Therapeutics’ current full-year earnings is ($0.22) per share. Capital One Financial also issued estimates for Heron Therapeutics’ Q2 2024 earnings at ($0.07) EPS, Q3 2024 earnings at ($0.06) EPS, Q4 2024 earnings at ($0.05) EPS, FY2024 earnings at ($0.28) EPS, FY2025 earnings at ($0.06) EPS, FY2026 earnings at $0.16 EPS, FY2027 earnings at $0.33 EPS and FY2028 earnings at $0.47 EPS.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings data on Tuesday, March 12th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.08. The firm had revenue of $34.23 million for the quarter, compared to analysts’ expectations of $30.98 million.

Other equities analysts have also issued research reports about the company. Needham & Company LLC reissued a “buy” rating and set a $5.00 price target on shares of Heron Therapeutics in a report on Thursday, April 11th. StockNews.com raised Heron Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, January 16th.

Heron Therapeutics Stock Down 5.4 %

NASDAQ HRTX opened at $2.65 on Thursday. Heron Therapeutics has a 52-week low of $0.50 and a 52-week high of $3.22. The business’s 50-day moving average price is $2.75 and its 200 day moving average price is $1.96. The firm has a market cap of $398.37 million, a P/E ratio of -3.08 and a beta of 1.68.

Institutional Investors Weigh In On Heron Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. Victory Capital Management Inc. lifted its position in Heron Therapeutics by 30.2% in the fourth quarter. Victory Capital Management Inc. now owns 19,929 shares of the biotechnology company’s stock valued at $34,000 after purchasing an additional 4,617 shares during the period. Commonwealth Equity Services LLC lifted its position in Heron Therapeutics by 5.5% in the third quarter. Commonwealth Equity Services LLC now owns 314,826 shares of the biotechnology company’s stock valued at $324,000 after purchasing an additional 16,467 shares during the period. Raymond James Financial Services Advisors Inc. lifted its position in Heron Therapeutics by 61.2% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 48,309 shares of the biotechnology company’s stock valued at $82,000 after purchasing an additional 18,333 shares during the period. Bank of New York Mellon Corp lifted its position in Heron Therapeutics by 5.8% in the third quarter. Bank of New York Mellon Corp now owns 353,395 shares of the biotechnology company’s stock valued at $364,000 after purchasing an additional 19,345 shares during the period. Finally, ACT Advisors LLC. acquired a new stake in Heron Therapeutics in the fourth quarter valued at about $38,000. Institutional investors and hedge funds own 80.01% of the company’s stock.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.